Save
esh.org
Indications for Allogeneic HSCT for Adult Acute Lymphoblastic Leukemia
ESH eLearning, Mark R. Litzow, 279753
Should MRD overcome baseline factors in risk assessment? Adult vs Paediatric opinions
ESH eLearning, Anthony Moorman, 279752
Antibody Conjugates in ALL
ESH eLearning, Hagop Kantarjian, 279751
Metabolism, disposition, and toxicity of ALL drugs
ESH eLearning, Mary V. Relling, 279750
JAK/STAT signaling in T-ALL
ESH eLearning, Pieter Van Vlierberghe, 279749
Targeting oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia
ESH eLearning, Jan Cools, 279748
The new taxonomy of B-ALL
ESH eLearning, Charles Mullighan, 279747
NO
ESH eLearning, Nelson LEUNG, 261677
YES
ESH eLearning, Bertrand Arnulf, 261663
Bispecific antibodies in the treatment of multiple myeloma
ESH eLearning, Hermann EINSELE, 261669
Antibody based immune therapy
ESH eLearning, Niels VAN DE DONK, 261689
Car-T cell in clinical practice
ESH eLearning, Hermann EINSELE, 261668
Meta-analyses - how to interpret and to translate to clinical practice
ESH eLearning, Robert Hills, 261673
Is this multiple myeloma? A patient with high serum light chains and renal failure
ESH eLearning, Stefan Knop, 261676
A patient with proteasome inhibitors- and immunomodulatory drugs -refractory disease
ESH eLearning, Salomon Manier, 261679
A transplant-eligible patient with a non-aggressive relapse 24 months after autologous stem cell transplant followed by lenalidomide maintenance
ESH eLearning, Francesca Gay, 261671
A transplant- ineligible patient with partial response after 12 cycles of lenalidomide-dexamethasone - to continue, to limit, to change?
ESH eLearning, Inger Nijhof, 261684
A transplant-eligible patient with an aggressive relapse 12 months after autologous stem cell transplant - what to do now?
ESH eLearning, Paula Rodriguez, 261687
Smouldering disease - from definition to treatment
ESH eLearning, Salomon Manier, 261672
How to manage side effects
ESH eLearning, Inger Nijhof, 261683
Late relapse
ESH eLearning, Stefan Knop, 261681
First relapse in transplant eligible
ESH eLearning, Sagar LONIAL, 261678
Waldenstrom Macroglobulinemia
ESH eLearning, Jorge Castillo, 261664
Monoclonal gammopathy of clinical significance
ESH eLearning, Angela DISPENZIERI, 261667
Amyloidosis from diagnosis to treatment
ESH eLearning, Giovanni Palladini, 261680
Transplant non-eligible
ESH eLearning, Thierry Facon, 261670
Transplant eligible
ESH eLearning, Michele Cavo, 261665
First relapse in transplant non eligible
ESH eLearning, KARTHIK Ramasamy, 261686
Bone disease - personalized limited treatment
ESH eLearning, Evangelos TERPOS, 261688
Bone disease - continuous treatment
ESH eLearning, Charlotte PAWLYN, 261685
Functional imaging characteristics of myeloma - promising now, predicting in the future?
ESH eLearning, Elena ZAMAGNI, 261690
What is old - from biology of the disease to patient
ESH eLearning, Sonja ZWEEGMAN, 261691
High risk disease - from definition to treatment
ESH eLearning, Jonathan KEATS, 261675
Double hit also in myeloma? The role of genome sequencing
ESH eLearning, Gareth MORGAN, 261682
Case-based lecture: CML in blast crisis
ESH eLearning, Massimo Breccia, 272258
Case-based lecture: IFN/TKI combination and IFN maintenance therapy in CML
ESH eLearning, Andreas Burchert, 272259
Pregnancy in CML and MPN
ESH eLearning, Jane Apperley, 272260
CML diagnosed in a pregnant woman
ESH eLearning, Jane Apperley, 272261
Finding the right time to start systemic therapy in PV after multiple phlebotomies
ESH eLearning, Claire Harrison, 272262
Asciminib: Results from the phase I study and perspectives of allosteric BCR-ABL1 inhibition
ESH eLearning, Delphine Réa, 272263
Case-based lecture: Diagnosis and risk stratification of MF
ESH eLearning, Alessandro Vannucchi, 272245
Case-based lecture: Management of myelofibrosis: excluding stem cell transplant
ESH eLearning, Ruben Mesa, 272246
Case-based lecture: Management of blast phase MPN
ESH eLearning, John Mascarenhas, 272247
Case-based lecture: Diagnosis and management of a CML and CNL
ESH eLearning, Jeffrey Tyner, 272248
Familial MPN: diagnosis and treatment
ESH eLearning, Jean-Christophe Ianotto, 272249
The young patient with myelofibrosis: To transplant or not to transplant
ESH eLearning, Claire Harrison, 272250
Case-based lecture: CML as an emergency: Initial management of patients with high tumour load
ESH eLearning, Andreas Hochhaus, 272251
Case-based lecture: Role of baseline cytogenetics and prognostic scores
ESH eLearning, Dragana Milojkovic, 272252
Case-based lecture: Role of concomitant disease and drug therapy for TKI selection
ESH eLearning, Delphine Réa, 272253
Case-based lecture: Milestones - Management of suboptimal response
ESH eLearning, Jeroen Janssen, 272254
To continue or to discontinue treatment in a CML patient in deep molecular response
ESH eLearning, Andreas Burchert, 272255
TKI therapy in a patient with CSFR3 mutated MPN
ESH eLearning, Jeffrey Tyner and Jason Gotlib, 272256
Case-based lecture: Diagnosis and management of non-PV erythrocytosis
ESH eLearning, Mary-Frances McMullin, 272238
Case-based lecture: Management of essential thrombocythaemia
ESH eLearning, Claire Harrison, 272239
Molecular predictors of outcome in MPN
ESH eLearning, Jyoti Nangalia, 272240
YES
ESH eLearning, Alessandro Vannucchi, 272241
NO
ESH eLearning, John Mascarenhas, 272242
Diagnosis and treatment initiation of CML
ESH eLearning, Andreas Hochhaus, 272243
Myelofibrosis: progression vs drug failure
ESH eLearning, Ruben Mesa, 272244
New Insights into the early-stage bone colonization of disseminated cancer cells
ESH eLearning, Xiang H.F. Zhang, 261707
Molecular regulation and heterogeneity in quiescence exit of human haematopoietic stem cells
ESH eLearning, Elisa Laurenti, 261706
Subversion of systemic glucose metabolism as a mechanism to support the growth of leukaemia cells
ESH eLearning, Haobin Ye, 261705
Fatty acid metabolism and bone marrow adipocytes in AML
ESH eLearning, Yoko Tabe, 261704
The HSC niche in aging
ESH eLearning, Hartmut Geiger, 263172
Genomic landscape of Waldenström’s macroglobulinemia
ESH eLearning, Steve Treon, 233978
POEMS syndromes
ESH eLearning, Arnaud Jaccard, 233979
How to judge the value of a clinical trial: HR, median PFS, p-value
ESH eLearning, Robert Hills, 233980
Real-world evidence –What is it and what can it tell us?
ESH eLearning, Kwee Yong, 233981
Optimal cost/safety/efficacy/QOL ration
ESH eLearning, Jean-Luc Harousseau, 233982
New generation sequencing in multiple myeloma
ESH eLearning, Nikhil Munshi, 233973
When and how to treat first relapse according to the guidelines
ESH eLearning, Meletios A Dimopoulos, 233974
New drugs, new immune therapies, new targeted therapies
ESH eLearning, Enrique Ocio, 233975
Adoptive cell therapy in multiple myeloma
ESH eLearning, Jesus Berdeja, 233976
Future combinations for the treatment of MM
ESH eLearning, Kenneth C. Anderson, 233977
From MGUS to MM: Do all clones take the same road?
ESH eLearning, Madhav Dhodapkar, 233965
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, María-Victoria Mateos, 233966
Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)
ESH eLearning, Hervé Avet-Loiseau, 233967
Primary plasma cell leukaemia and extramedullary disease
ESH eLearning, Niels VAN DE DONK, 233968
Geriatric assessment: is it required?
ESH eLearning, Alessandra Larocca, 233969
Geriatric assessment in multiple myeloma: is it required?
ESH eLearning, Alessandra Larocca, 234000
MRD as a response assessment in elderly multiple myeloma
ESH eLearning, Alessandra Larocca, 234001
Vaccines to prevent progression or relapse in multiple myeloma
ESH eLearning, Ann van de Velde, 234002
The evolving imaging of multiple myeloma
ESH eLearning, Evangelos Terpos, 234013
Real world data: bortezomib-based therapy for R/R myeloma
ESH eLearning, Evangelos Terpos, 234014
Real world data for len/dex in second-line myeloma: what does this tell us?
ESH eLearning, Evangelos Terpos, 234015
Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM
ESH eLearning, Evangelos Terpos, 234016
Treatment sequencing in multiple myeloma: a multitude of options
ESH eLearning, Heinz Ludwig, 234017
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
ESH eLearning, Heinz Ludwig, 234018
Combining bortezomib and lenalidomide-based regimens for frontline MM
ESH eLearning, Kwee Yong, 234029
Real world evidence: what is it and what can it tell us?
ESH eLearning, Kwee Yong, 234030
How should smoldering multiple myeloma be monitored?
ESH eLearning, María-Victoria Mateos, 234031
Update on recent smoldering multiple myeloma trials
ESH eLearning, María-Victoria Mateos, 234032
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
ESH eLearning, María-Victoria Mateos, 234033
Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
ESH eLearning, María-Victoria Mateos, 234034
PVX-410 vaccine for smoldering myeloma
ESH eLearning, Noopur Raje, 234045
Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
ESH eLearning, Noopur Raje, 234046
Judging the value of a clinical trial in hem-onc
ESH eLearning, Robert Hills, 234047
Opinion: value of MRD as an endpoint in hem-onc clinical trials
ESH eLearning, Robert Hills, 234048
UK NCRI AML17 trial update: everolimus addition for consolidation
ESH eLearning, Robert Hills, 234049
Monoclonal antibodies: current and future potential
ESH eLearning, Saad Usmani, 234050

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings